计算溶液所需的质量、体积或浓度。
为什么选择此级别
提供 ≥98% 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
避光,-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research.
In Vitro
Alteminostat (CKD-581; 1 nM-10 μM; 72 hours) treatment potently reduces cell viability in all four lymphoma cell lines in a concentration-dependent manner. The IC50 values of Alteminostat in SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells are 1.31 nM, 36.91 nM, 1.18 nM, and 31.99 nM, respectively. Alteminostat (CKD-581; 10-300 nM; 24 hours) treatment decreases the expression of BCL-6 as well as BCL-2 in cells. Alteminostat (CKD-581; 30-300 nM; 24 h) treatment results in γH2AX accumulation and PARP1 cleavage in SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells. Alteminostat decreases the protein levels of BCL-XL and MCL-1 in a concentration-dependent manner in OCI-LY1 cells. Alteminostat (CKD-581; 10-300 nM; 6 hours) treatment increases the acetylation of histone H3 in SU-DHL-2 cells. And tubulin acetylation also increased with 10 nM CKD-581. CKD-581 increased the acetylation of target molecules by inhibiting class I-II HDACs in lymphoma cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells Concentration: 1 nM-10 μM Incubation Time: 72 hours Result: Potently reduced cell viability in all four lymphoma cell lines in a concentration-dependent manner. Western Blot AnalysisCell Line: SU-DHL-4 and OCI-LY1 cells Concentration: 10 nM, 30 nM, 100 nM, 300 nM Incubation Time: 24 hours Result: Decreased the expression of BCL-6 as well as BCL-2 in cells.
In Vivo
Alteminostat (CKD-581; 20-40 mg/kg; ntraperitoneal injection; twice a week; for 4 weeks) treatment partially but significantly suppresses tumor growth in SU-DHL-4 xenograft mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male NOD.CB17 SCID injected with SU-DHL-4 cells Dosage: 20 mg/kg or 40 mg/kg Administration: Intraperitoneal injection; twice a week; for 4 weeks Result: Partially but significantly suppressed tumor growth.
Form:Solid
规格
别名
阿替诺特
规格或纯度
≥98%
英文名称
Alteminostat
生化机理
Alteminostat (CKD-581) 是一种强效的 HDAC 抑制剂。Alteminostat 可通过组蛋白 H3 和微管蛋白乙酰化抑制 I-II 类 HDAC 家族。Alteminostat 可用于淋巴瘤和多发性骨髓瘤研究。
储存条件
避光,-20°C储存
运输条件
超低温运输
作用类型
抑制剂
纯度
≥98%
名称和识别符
分子类型
小分子
Isomeric SMILES
CN1CCN(CC1)C(=O)N(CCCCCCC(=O)NO)C2=CC=C(C=C2)C3=CC4=C(C=C3)C=NN4C
PubChem CID
分子量
492.61
技术文档
高级数据
化学和物理性质
分子量
492.600 g/mol
XLogP3
2.800
氢键供体数Hydrogen Bond Donor Count
2
氢键受体数Hydrogen Bond Acceptor Count
5
可旋转键计数Rotatable Bond Count
9
精确质量Exact Mass
492.285 Da
单同位素质量Monoisotopic Mass
492.285 Da
拓扑极表面积Topological Polar Surface Area
93.900 Ų
重原子数Heavy Atom Count
36
形式电荷Formal Charge
0
复杂度Complexity
708.000
同位素原子数Isotope Atom Count
0
定义的原子立体中心计数Defined Atom Stereocenter Count
0
未定义的原子立体中心计数Undefined Atom Stereocenter Count
0
定义的键立体中心计数Defined Bond Stereocenter Count
0
未定义的键立体中心计数Undefined Bond Stereocenter Count
0
所有立体化学键的总数The total count of all stereochemical bonds
0
共价键合单元计数Covalently-Bonded Unit Count
1
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）